Unhappy with existing methods for delivering stem cells to the heart, a team of researchers has developed an exosome solution that can be sprayed through a tiny incision.
The 'right to repair' debate is one that could impact heart teams and device manufacturers for years to come. Some hospitals have had a head start, accusing one company of unfair repair policies that put patients at risk.